PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. Academic Article uri icon

Overview

abstract

  • We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8+ cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially available immunohistochemical assays, but amplification of CD274 (coding for PD-L1) and/or PDCD1LG2 (encoding PD-L2) by fluorescence in situ hybridization. RNA-seq revealed multiple biomarkers of an ongoing immune response and compensatory immune evasion, including moderate PD-L1 levels coupled with robust PD-L2 expression. Pending validation in additional patients, these findings suggest that PD-L2 expression levels may constitute a biomarker of response to immune checkpoint blockade in urothelial carcinoma.

publication date

  • May 29, 2018

Identity

PubMed Central ID

  • PMC6279415

Scopus Document Identifier

  • 85047660706

Digital Object Identifier (DOI)

  • 10.1038/nature23669

PubMed ID

  • 30524881

Additional Document Info

volume

  • 7

issue

  • 12